Valeant Pharmaceuticals International
Valeant Pharmaceuticals Reports Positive Phase III Results for Retigabine in RESTORE 1
Published in Medical Letter on the CDC and FDA, March 2nd, 2008
Valeant Pharmaceuticals International (NYSE:VRX) reported positive results for retigabine in RESTORE 1, the first of two Phase III pivotal trials, for this first-in-class neuronal potassium channel opener. Retigabine is being developed as an adjunctive treatment for adult epilepsy patients with refractory partial-onset seizures. RESTORE 1 evaluated the 1200 mg daily dose of retigabine (the highest dose in the RESTORE program) versus placebo in patients taking stable doses of 1 - 3 additional anti-epileptic drugs (AEDs). Retigabine demonstrated statistically significant results on the primary efficacy endpoints important for regulatory review by both the US Food and Drug Administration...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Malaria
Fake antimalarial drugs analysis highlights threat to global health - Innovations Facial Plastic Surgery
Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles - Metabolism
Marshfield Clinic Discovers Gene Variant Which Will Significantly Enhance the Accuracy of Molecular Tests for Warfarin Metabolism - Regulatory Actions
Edgeline Holdings Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000 - Diabetes Clinical Trial
Data on diabetes clinical trial reported by researchers at NHS Foundation Trust - Anthrax
Research from California State University in the area of anthrax published - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
